
United Therapeutics (UTHR) Stock
Biotech cash machine funding bioengineered lung research. Here's the price, business snapshot, and what's worth knowing about United Therapeutics in November 2026.
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It’s Moving

United Therapeutics Marks Milestone with First Xenotransplant in EXTEND Trial
- The company completed the first transplant in its EXTEND study of UThymoKidney™ at NYU Langone Health, targeting patients ineligible for conventional kidney transplants.
- Executives highlighted a robust $833 million quarter and discussed preparing for a potential expansion of the TYVASO franchise into idiopathic pulmonary fibrosis.
- Recent conference presentations emphasized a pipeline of upcoming regulatory and clinical milestones alongside current sales strength.

United Therapeutics Marks Milestone with First Xenotransplant in EXTEND Trial
- The company completed the first transplant in its EXTEND study of UThymoKidney™ at NYU Langone Health, targeting patients ineligible for conventional kidney transplants.
- Executives highlighted a robust $833 million quarter and discussed preparing for a potential expansion of the TYVASO franchise into idiopathic pulmonary fibrosis.
- Recent conference presentations emphasized a pipeline of upcoming regulatory and clinical milestones alongside current sales strength.
Six-Month Growth Performance
When is the next earnings date for UNITED THERAPEUTICS CORP (UTHR)?
No confirmed upcoming earnings date has been announced for UTHR as of November 16, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous release, the next report is expected in February 2027. This upcoming announcement will likely cover the fourth quarter and full-year results for fiscal year 2026. Investors should monitor official communications for the precise scheduling of this anticipated release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying United Therapeutics stock, believing it has potential to rise in value.
Financial Health
United Therapeutics is performing well with strong profits and cash flow, indicating healthy financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.